Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.
The BC-1 cell line, derived from a body cavity-based, B-cell lymphoma, is dually infected with Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV). In these studies, the relationships between these two gammaherpesviruses and BC-1 cells were characterized and compared. Single-cell cloning experiments suggested that all BC-1 cells contain both genomes. In more than 98% of cells, both viruses were latent. The two viruses could be differentially induced into their lytic cycles by chemicals. EBV was activated into DNA replication and late-gene expression by the phorbol ester tetradecanoyl phorbol acetate (TPA). KSHV was induced into DNA replication and late-gene expression by n-butyrate. Amplification of both EBV and KSHV DNAs was inhibited by phosphonoacetic acid. Induction of the KSHV lytic cycle by n-butyrate was accompanied by the disappearance of host-cell beta-actin mRNA. Induction of EBV by TPA was not accompanied by such an effect on host-cell gene expression. Induction of the KSHV lytic cycle by n-butyrate was associated with the expression of several novel polypeptides. Recognition of one of these, p40, served as the basis of development of an assay for antibodies to KSHV in the sera of infected patients. BC-1 cells released infectious EBV; however, there was no evidence for the release of encapsidated KSHV genomes by BC-1 cells, even though n-butyrate-treated cells contained numerous intranuclear nucleocapsids. The differential inducibility of these two herpesviruses in the same cell line points to the importance of viral factors in the switch from latency to lytic cycle.
Miller
G
G
Yale University School of Medicine, New Haven, Connecticut 06520, USA. George_Miller@qm.yale.edu
Heston
L
L
Grogan
E
E
Gradoville
L
L
Rigsby
M
M
Sun
R
R
Shedd
D
D
Kushnaryov
V M
VM
Grossberg
S
S
Chang
Y
Y
D000818:Animals; D000956:Antigens, Viral; D002087:Butyrates / Q000494:pharmacology; D020148:Butyric Acid; D004261:DNA Replication; D004279:DNA, Viral / Q000032:analysis; D016679:Genome, Viral; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D019288:Herpesvirus 8, Human / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000473:pathology / Q000821:virology*; D008854:Microscopy, Electron; D010452:Peptide Biosynthesis; D010746:Phosphonoacetic Acid / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger; D012367:RNA, Viral / Q000032:analysis; D011817:Rabbits; D012514:Sarcoma, Kaposi / Q000821:virology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014771:Virion; D017735:Virus Latency; D014779:Virus Replication
D000956:Antigens, Viral; D002087:Butyrates; D004279:DNA, Viral; D012333:RNA, Messenger; D012367:RNA, Viral; D020148:Butyric Acid; D010746:Phosphonoacetic Acid; D013755:Tetradecanoylphorbol Acetate